ABBVAbbVie Inc.
- US FDA
Approval of Canasa, Nda #021252 (Labeling)
Approval Date: 10/14/2026; Drug Name: Canasa, Nda #021252; Active Ingredients: MESALAMINE; Company: Abbvie; Submission Status: Approval; Submission Classification: Labeling; Application Number: 021252 ...
- Analyst Upgrades
RBC Capital Reiterates Outperform on AbbVie, Maintains $280 Price Target
RBC Capital analyst Trung Huynh reiterates AbbVie with a Outperform and maintains $280 price target. ...
- Analyst Upgrades
UBS Maintains Neutral on AbbVie, Raises Price Target to $275
UBS analyst Michael Yee maintains AbbVie with a Neutral and raises the price target from $260 to $275. ...
- Analyst Upgrades
Guggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target
Guggenheim analyst Vamil Divan reiterates AbbVie with a Buy and maintains $288 price target. ...
- Analyst Upgrades
JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300
JP Morgan analyst Chris Schott maintains AbbVie with a Overweight and raises the price target from $285 to $300. ...
- Analyst Upgrades
Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290
Cantor Fitzgerald analyst Carter Gould maintains AbbVie with a Overweight and raises the price target from $285 to $290. ...
- Analyst Upgrades
Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $310
Morgan Stanley analyst Terence Flynn maintains AbbVie with a Overweight and raises the price target from $296 to $310. ...
- PR Newswire
AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for... ...
- Analyst Upgrades
Scotiabank Maintains Sector Outperform on AbbVie, Raises Price Target to $320
Scotiabank analyst Louise Chen maintains AbbVie with a Sector Outperform and raises the price target from $280 to $320. ...
- PR Newswire
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed... ...
- BusinessWire
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline ...
- PR Newswire
AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
AbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg... ...
- PR Newswire
AbbVie to Host Third-Quarter 2026 Earnings Conference Call
AbbVie (NYSE: ABBV) will announce its third-quarter 2026 financial results on Friday, October 30, 2026, before the market opens. AbbVie will host a... ...
- PR Newswire
AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
AbbVie (NYSE: ABBV) today announced that detailed results from the multiple ascending dose (MAD) part of its Phase 1 study evaluating ABBV-295 will... ...
- PR Newswire
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
AbbVie (NYSE: ABBV) today announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study, evaluating... ...
- PR Newswire
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
AbbVie (NYSE: ABBV) today announced new research across its diverse dermatology portfolio to be presented at the 2026 European Academy of Dermatology ... ...
- PR Newswire
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development
AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI... ...
- PR Newswire
U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only... ...
- US FDA
Approval of Juvmo, Nda #220415 (Type 1 - New Molecular Entity)
Approval Date: 09/25/2026; Drug Name: Juvmo, Nda #220415; Active Ingredients: TAVAPADON; Company: Abbvie Inc; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 220415 ...
- PR Newswire
Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), the global industry leader in aesthetics, today announced the U.S. launch of AA Signature™.... ...
- PR Newswire
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral... ...
- PR Newswire
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
AbbVie (NYSE: ABBV) and Iambic, a clinical-stage life sciences and technology company developing novel medicines through its AI-driven discovery and... ...
- PR Newswire
AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026
AbbVie (NYSE: ABBV) today presented new VRAYLAR® (cariprazine) data at Psych Congress 2026 in New Orleans, including results from two prospective... ...
- PR Newswire
AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
AbbVie (NYSE: ABBV) announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23rd International... ...
- PR Newswire
Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced results from two single-center clinical studies evaluating targeted skincare... ...